Inogen Inc ( (INGN) ) has released its Q3 earnings. Here is a breakdown of the information Inogen Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Inogen, Inc. is a global medical technology company specializing in innovative respiratory products for homecare settings, aimed at improving the lives of patients with chronic respiratory conditions through advanced therapy devices.
In its third quarter of 2025, Inogen reported a revenue of $92.4 million, marking a 4.0% increase from the previous year, continuing its trend of mid-single-digit growth for the seventh consecutive quarter. The company also reiterated its full-year revenue guidance while raising its adjusted EBITDA expectations.
Key financial highlights include a GAAP net loss of $5.3 million, an improvement from the previous year’s $6.0 million loss, and an adjusted net loss of $0.5 million compared to $2.6 million in the prior year. The company achieved a positive adjusted EBITDA of $2.3 million and generated $2.2 million in operating cash flow, bolstering its cash reserves to $124.5 million. Additionally, Inogen launched a limited market release of its Simeox airway clearance device in the U.S.
Inogen’s management remains optimistic about the future, focusing on sustained revenue growth and operational improvements. The company aims to continue its leadership in respiratory care, with a commitment to delivering innovative solutions and building long-term value for shareholders.